Abstract Number: 3004 • 2016 ACR/ARHP Annual Meeting
The Choosing Wisely Initiative: Is It Complete?
Background/Purpose: Low back pain is a highly prevalent problem affecting approximately 70-85% of Americans in their lifetime (1). American College of Physicians (ACP) has recommended…Abstract Number: 3005 • 2016 ACR/ARHP Annual Meeting
Development and Initial Validation of the “MH Score”, a New Diagnostic Tool That Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Background/Purpose: It is common view that macrophage activation syndrome (MAS) bears close similarities with primary hemophagocytic lymphohistiocytosis (pHLH). The resemblance of their clinical and laboratory…Abstract Number: 3006 • 2016 ACR/ARHP Annual Meeting
IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Background/Purpose: Evidence in animals and humans points to a pivotal role of IFNγ in primary HLH. We have recently generated data in an animal model…Abstract Number: 3007 • 2016 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN)…Abstract Number: 3008 • 2016 ACR/ARHP Annual Meeting
Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium
Background/Purpose: Although the recommended first line treatment for JIA, up to 50% of children will not respond to MTX. Currently, it is not possibly to…Abstract Number: 3009 • 2016 ACR/ARHP Annual Meeting
Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic inflammatory rheumatic diseases of childhood. Due to their long-term safety and efficacy, biologic disease modifying…Abstract Number: 3010 • 2016 ACR/ARHP Annual Meeting
Improvement of Spinal Inflammation Induced By Etanercept in Enthesitis Related Arthritis JIA-Patients. Data of the Reminder-Study
Background/Purpose: The data of the REMINDER study, a two-part, 48-week, randomized, placebo-controlled, double-blind withdrawal study on efficacy of etanercept (ETA) compared to placebo (PLC) in…Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study
Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…Abstract Number: 3012 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of TNF-Inhibitor Free Disease Control in Patients with Rheumatoid Arthritis after Stopping TNFi Treatment: Results from a Dutch Multicentre Pragmatic Open-Label Randomized Controlled Trial.
Background/Purpose: Tumor Necrosis Factor inhibitor (TNFi) free prolonged acceptable disease control in patients with rheumatoid arthritis (RA), in stable remission or low disease activity…Abstract Number: 3013 • 2016 ACR/ARHP Annual Meeting
Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Background/Purpose: Dose tapering in patients in remission has previously proven promising in randomized controlled trials. However, systematic implementation in clinical practice is lacking. A new…Abstract Number: 3014 • 2016 ACR/ARHP Annual Meeting
Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis
Background/Purpose: Treatment with biologicals is based on the principle of ‘one size fits all’ without taking differences into account for dosing schemes, patients’ characteristics and…Abstract Number: 3015 • 2016 ACR/ARHP Annual Meeting
The Good, the Bad and the Ugly – Refractory Rheumatoid Arthritis in 2016
Background/Purpose: Rheumatoid arthritis (RA) is characterised by the presence of a progressively destructive joint inflammation. Even in times of modern therapeutics, a subgroup of patients…Abstract Number: 3016 • 2016 ACR/ARHP Annual Meeting
Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis
Background/Purpose: The original Disease Activity Score (DAS) was derived from clinicians’ therapeutic decisions1, which may have been influenced by patient-subjective factors such as general health…Abstract Number: 3017 • 2016 ACR/ARHP Annual Meeting
Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
Background/Purpose: The initial site of anti-citrullinated protein antibody (ACPA) generation in RA has been proposed to be a mucosal site. We have previously demonstrated ACPA…Abstract Number: 3018 • 2016 ACR/ARHP Annual Meeting
The Analysis of Severity of Arthritis in the Intestinal Microbiota-Humanized Mice
Background/Purpose: Although various genetic factors have been implicated in susceptibility to rheumatoid arthritis (RA), environmental factors including smoking, periodontal disease and hormones are also necessary…
ACR Meeting Abstracts